Enhabit, Inc. (EHAB) Presents at UBS Global Healthcare Conference 2025 Transcript

Enhabit, Inc. (EHAB) management highlighted strong 2025 performance, citing continued outperformance in hospice and successful home health payer negotiations that have significantly contributed to deleveraging. The company is confident in its ability to offset potential negative impacts from the pending CMS home health rule through strategic initiatives, including a pilot program reducing visits per episode (e.g., 15 to 13, valued at $5M-$8M per half-visit reduction), cost discipline, and organic growth, including 10 annual de novo locations leaning towards hospice. Reduced leverage provides flexibility for technology investments and selective strategic M&A, though the home health M&A market faces buyer-seller valuation mismatches pending regulatory clarity.

Analysis

Enhabit (EHAB) reported a strong 2025 performance, driven by continued outperformance in its hospice segment and successful home health payer negotiations, which have significantly contributed to deleveraging. The company's strategic focus on organic growth and de novo expansion, particularly in hospice (targeting 6-7 of 10 annual de novos), has yielded positive results, with management highlighting the durability of hospice margins and the positive impact of payer strategy on home health.

Despite potential headwinds from the pending CMS home health rule, EHAB expresses confidence in its ability to mitigate negative impacts. A pilot program reducing home health visits per episode from 15 to 13, valued at $5M-$8M per half-visit reduction, is being rolled out to all locations by the end of November. This, combined with cost discipline and leveraging freed-up capacity with additional patient volume, is expected to meaningfully offset any proposed rate reductions.

The company has reduced over 1.5 turns of leverage since Q4 2023, providing increased balance sheet flexibility. This newfound capacity will support investments in technology, accelerate the de novo strategy, and enable selective, strategic M&A. While hospice M&A remains "frothy," the upcoming CMS rule is anticipated to bring clarity to home health valuations, potentially resolving the current buyer-seller mismatch and creating future acquisition opportunities.

Key Decisions for Investors

• Monitor the final CMS home health rule publication by early December for clarity on potential rate adjustments and its impact on EHAB's home health segment.
• Evaluate EHAB's execution of its visit-per-episode reduction pilot and its ability to maintain quality outcomes while achieving cost savings, as this is key to mitigating regulatory risks.
• Consider the enhanced balance sheet flexibility and strategic M&A potential, particularly in home health post-CMS clarity, as drivers for future growth and market consolidation.